Summary:
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Criteria:- Must have a history of slow memory decline over the last 6 months
- must have 1 informant/care partner
- Must be in good health
Qualified Participants May Receive:
Compensation for time and travel if they meet the criteria to join the study, along with MRI and PET scans provided at no cost.